Celebrating our research achievements
7 April 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) were among the 180 health industry staff, researchers and students whose awards were highlighted at the annual Sydney Medical School’s Celebratory Dinner on 30 March 2017. The evening celebrated the achievements of staff and students from The University of Sydney and its affiliates, like MIA, who have received significant awards during past year.
MIA’s researchers were recognised and celebrated due to their outstanding contributions to health research in Australia.
- Professor John Thompson AO was celebrated for receiving an Honorary Doctorate from Macquarie University and for being named Honorary Fellow of the American College of Surgeons.
- Dr James Wilmott was celebrated for receiving the ‘Wildfire’ Highly Cited Publication Award at the NSW Premier’s Award for Outstanding Cancer Research.
5 Minutes with Maria Gonzalez
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
Melanoma eBook to educate GPs
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
5 Minutes with Dr Scot Ebbinghaus
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
Opdivo available on PBS for advanced melanoma patients
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
5 Minutes with Dr Louise Jackett
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA patient's plight highlighted in ABC series
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Recruiting: Pregnancy and moles study
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
The role of radiotherapy in melanoma
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
Australian melanoma rates take the silver – and that's good news
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Australia unites taking small steps to make a big difference for melanoma research
Thank you to everyone involved in making Melanoma March 2016 a huge success
And they're off... Melanoma March 2016 begins!
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
5 Minutes with Carole Renouf
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
Opinion: Outing Melanoma
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
Congratulations Professor Georgina Long
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016: Where your funds are going
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March 2016 is launched
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
MIA's research pivotal in TGA's approval of new therapy
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
The Face of Melanoma March
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
Q&A With An Expert: Dermatologist
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.